Peregrine Pharmaceuticals - PPHM - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Peregrine Pharmaceuticals - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
PPHM	Nasdaq	8731	http://www.peregrineinc.com	1.83 0.00
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Peregrine Pharmaceuticals These Winners Couldn't Send the Dow to Another Record - May 20th, 2013 6:02 pm Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trials - May 20th, 2013 2:10 pm Small-cap makes a splash with FDA nod for cancer drug - May 20th, 2013 1:16 pm Movers roundup: WPX Energy, Peregrine - May 20th, 2013 12:39 pm Movers roundup: WPX Energy, Peregrine - May 20th, 2013 12:39 pm Why Peregrine Pharmaceuticals Shares Skyrocketed - May 20th, 2013 11:58 am Peregrine rises on agreement for late-stage study - May 20th, 2013 11:15 am Peregrine rises on agreement for late-stage study - May 20th, 2013 11:15 am Apple Explores OLED For Its Smartwatch and 2 Other Hot Stocks to Watch - May 20th, 2013 10:58 am Peregrine Pharma agrees with FDA on lung cancer trial design - May 20th, 2013 7:36 am PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - May 20th, 2013 7:16 am Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer - May 20th, 2013 6:47 am InPlay: Peregrine Pharma halted - May 20th, 2013 6:44 am Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting - May 16th, 2013 6:30 am Osiris Loss In-Line with Expectations - May 8th, 2013 3:55 pm PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers - May 8th, 2013 8:14 am Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential - May 3rd, 2013 8:18 pm Is Peregrine Preparing to Soar Again? - Apr 29th, 2013 6:14 pm 4 Healthcare Stock Stories To Kick Off the Trading Week - Apr 29th, 2013 4:22 pm Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab - Apr 29th, 2013 6:30 am View All Current Headlines >>